Company’s 36-month beta value is 1.10.Analysts have differing opinions on the stock, with 9 analysts rating it as a “buy,” 4 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for RVMD is 161.93M, and currently, short sellers hold a 10.22% ratio of that floaft. The average trading volume of RVMD on May 22, 2025 was 1.79M shares.
RVMD) stock’s latest price update
The stock price of Revolution Medicines Inc (NASDAQ: RVMD) has dropped by -4.27 compared to previous close of 40.47. Despite this, the company has seen a fall of -1.87% in its stock price over the last five trading days. globenewswire.com reported 2025-05-14 that REDWOOD CITY, Calif., May 14, 2025 (GLOBE NEWSWIRE) — Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced the first patient has been dosed in RASolve 301, a global, randomized, open-label Phase 3 clinical trial.
RVMD’s Market Performance
Revolution Medicines Inc (RVMD) has experienced a -1.87% fall in stock performance for the past week, with a 5.10% rise in the past month, and a -8.33% drop in the past quarter. The volatility ratio for the week is 3.58%, and the volatility levels for the past 30 days are at 4.58% for RVMD.. The simple moving average for the past 20 days is -2.89% for RVMD’s stock, with a -11.46% simple moving average for the past 200 days.
Analysts’ Opinion of RVMD
Many brokerage firms have already submitted their reports for RVMD stocks, with Needham repeating the rating for RVMD by listing it as a “Buy.” The predicted price for RVMD in the upcoming period, according to Needham is $62 based on the research report published on July 16, 2024 of the previous year 2024.
Barclays, on the other hand, stated in their research note that they expect to see RVMD reach a price target of $52. The rating they have provided for RVMD stocks is “Overweight” according to the report published on July 12th, 2024.
Jefferies gave a rating of “Buy” to RVMD, setting the target price at $63 in the report published on July 08th of the previous year.
RVMD Trading at 2.47% from the 50-Day Moving Average
After a stumble in the market that brought RVMD to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -37.92% of loss for the given period.
Volatility was left at 4.58%, however, over the last 30 days, the volatility rate increased by 3.58%, as shares surge +3.47% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -0.39% lower at present.
During the last 5 trading sessions, RVMD fell by -1.87%, which changed the moving average for the period of 200-days by -11.95% in comparison to the 20-day moving average, which settled at $39.89. In addition, Revolution Medicines Inc saw -11.43% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at RVMD starting from Cislini Jeff, who sale 2,041 shares at the price of $38.71 back on Mar 20 ’25. After this action, Cislini Jeff now owns 57,723 shares of Revolution Medicines Inc, valued at $79,008 using the latest closing price.
JEFFREY TODD CISLINI, the Officer of Revolution Medicines Inc, proposed sale 2,041 shares at $38.75 during a trade that took place back on Mar 20 ’25, which means that JEFFREY TODD CISLINI is holding shares at $79,089 based on the most recent closing price.
Stock Fundamentals for RVMD
The total capital return value is set at -0.36. Equity return is now at value -36.68, with -32.64 for asset returns.
Based on Revolution Medicines Inc (RVMD), the company’s capital structure generated 0.06 points at debt to capital in total, while cash flow to debt ratio is standing at -4.4.
Currently, EBITDA for the company is -589.02 million with net debt to EBITDA at 0.26. The liquidity ratio also appears to be rather interesting for investors as it stands at 13.46.
Conclusion
In a nutshell, Revolution Medicines Inc (RVMD) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
